GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Intrinsic Value: Projected FCF

Belluscura (FRA:9VQ) Intrinsic Value: Projected FCF : €0.00 (As of May. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Belluscura Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-30), Belluscura's Intrinsic Value: Projected FCF is €0.00. The stock price of Belluscura is €0.162. Therefore, Belluscura's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Belluscura's Intrinsic Value: Projected FCF or its related term are showing as below:

FRA:9VQ's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.72
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Belluscura Intrinsic Value: Projected FCF Historical Data

The historical data trend for Belluscura's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Intrinsic Value: Projected FCF Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
- - - - -

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Belluscura's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Belluscura's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belluscura's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Belluscura's Price-to-Projected-FCF falls into.



Belluscura Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Belluscura  (FRA:9VQ) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Belluscura's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.162/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Belluscura Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Belluscura's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Belluscura (FRA:9VQ) Business Description

Traded in Other Exchanges
Address
15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines